Article
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Molecular neurodegeneration - 3 Sept 2015
Neumann Ulf, Rueeger Heinrich, Machauer Rainer, Veenstra Siem Jacob, Lueoend Rainer M, Tintelnot-Blomley Marina, Laue Grit, Beltz Karen, Vogg Barbara, Schmid Peter, Frieauff Wilfried, Shimshek Derya R, Staufenbiel Matthias, Jacobson Laura H
Abstract excerpt
BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt, disease progression. Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being causal for the neurodegeneration and dementia typical of AD. Approaches to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.